Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New hope for arthritis: korean study tests Filgotinib's power

NCT ID NCT06625242

First seen Nov 01, 2025 · Last updated May 17, 2026 · Updated 21 times

Summary

This study tested the drug filgotinib in 118 Korean adults with rheumatoid arthritis, an autoimmune disease that causes joint pain and swelling. The main goal was to see how many patients had at least a 20% improvement in symptoms after 12 weeks of treatment. The study is complete, and results will show how well filgotinib controls the disease in this specific population.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Eisai site #01

    Busan, South Korea

  • Eisai site #02

    Gwangju, South Korea

  • Eisai site #03

    Seoul, South Korea

  • Eisai site #04

    Seoul, South Korea

  • Eisai site #05

    Seoul, South Korea

  • Eisai site #06

    Daejeon, South Korea

  • Eisai site #07

    Seoul, South Korea

  • Eisai site #08

    Seoul, South Korea

  • Eisai site #09

    Daegu, South Korea

  • Eisai site #10

    Seoul, South Korea

  • Eisai site #11

    Anyang-si, South Korea

  • Eisai site #12

    Daegu, South Korea

  • Eisai site #13

    Incheon, South Korea

  • Eisai site #14

    Seoul, South Korea

  • Eisai site #15

    Guri-si, South Korea

Conditions

Explore the condition pages connected to this study.